Cargando…

Comparison of Antidiabetic Regimens in Patients with Type 2 Diabetes Uncontrolled by Combination Therapy of Sulfonylurea and Metformin: Results of the MOHAS Disease Registry in Korea

BACKGROUND: The aim of this study was to investigate the glucose-lowering efficacy of antidiabetic treatments in patients with type 2 diabetes mellitus (T2DM) uncontrolled by sulfonylurea plus metformin. METHODS: This open-label, multicenter, prospective, observational study was conducted in 144 cen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Sung Hee, Oh, Tae Jung, Jang, Hak Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489497/ https://www.ncbi.nlm.nih.gov/pubmed/28537056 http://dx.doi.org/10.4093/dmj.2017.41.3.170

Ejemplares similares

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis
por: Bodmer, Michael, et al.
Publicado: (2008)

Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea
por: Kim, Sin Gon, et al.
Publicado: (2015)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Chronic Antidiabetic Sulfonylureas In Vivo: Reversible Effects on Mouse Pancreatic β-Cells
por: Remedi, Maria Sara, et al.
Publicado: (2008)

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis
por: Qian, Dan, et al.
Publicado: (2018)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma
por: Toomey, Paul, et al.
Publicado: (2017)

Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
por: Oosterom, Nicole, et al.
Publicado: (2022)

Antidiabetic Effects of Add-On Gynostemma pentaphyllum Extract Therapy with Sulfonylureas in Type 2 Diabetic Patients
por: Huyen, V. T. T., et al.
Publicado: (2012)

Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea
por: Kim, Hye-soon, et al.
Publicado: (2014)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum
Publicado: (2017)

The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
por: Boddepalli, Chinmayi Sree, et al.
Publicado: (2022)

Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea
por: Kim, Jung Hee, et al.
Publicado: (2011)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Improvements in Glycemic Control in Type 2 Diabetes Patients Switched From Sulfonylurea Coadministered With Metformin to Glyburide-Metformin Tablets
por: Duckworth, Wiliam
Publicado: (2003)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas
por: Chu, Patricia Y., et al.
Publicado: (2020)

Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea
por: Baker, Matthew C., et al.
Publicado: (2023)

Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs
por: Volke, Vallo, et al.
Publicado: (2022)

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
por: Kim, Kyuho, et al.
Publicado: (2021)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
por: Qian, Dan, et al.
Publicado: (2018)

Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
por: Kim, Chul-Hee, et al.
Publicado: (2012)

Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
por: Mearns, Elizabeth S., et al.
Publicado: (2015)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016)

Low Branched Chain Amino Acids and Tyrosine in Thai Patients with Type 2 Diabetes Mellitus Treated with Metformin and Metformin-Sulfonylurea Combination Therapies
por: Sriboonvorakul, Natthida, et al.
Publicado: (2021)

Increased risk of metabolic disorders in healthy young adults with family history of diabetes: from the Korea National Health and Nutrition Survey
por: Moon, Joon Ho, et al.
Publicado: (2017)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

Outcome and status of postcardiac arrest care in Korea: results from the Korean Hypothermia Network prospective registry
por: Kim, Soo Hyun, et al.
Publicado: (2020)

SUDOSCAN in Combination with the Michigan Neuropathy Screening Instrument Is an Effective Tool for Screening Diabetic Peripheral Neuropathy
por: Oh, Tae Jung, et al.
Publicado: (2022)

Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial
por: Lee, Seung-Eun, et al.
Publicado: (2019)

Sulfonylurea antidiabetics are associated with lower risk of out‐of‐hospital cardiac arrest: Real‐world data from a population‐based study
por: Eroglu, Talip E., et al.
Publicado: (2021)

Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study
por: Mamza, Jil, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fdpvqt1hgqi4doblqirmb8080b